Key Takeaways
- •Proscia leads US digital pathology KLAS rankings.
- •Proscia earned A+ grades across six experience pillars.
- •Porosome.AI designs BBB‑penetrant porosome drugs.
- •AI‑driven peptides target secretory disorders.
- •Organoid studies show Alzheimer’s pathology reversal.
Summary
Proscia has been crowned the top‑performing digital pathology software vendor in the United States, receiving a 95.2 overall score in KLAS Research’s 2026 report and earning A+ or A grades across all six customer‑experience pillars. The company is also the most frequently considered platform by labs evaluating digital pathology solutions and the first to top KLAS rankings in multiple regions within a single year. Meanwhile, Porosome Therapeutics unveiled its Porosome.AI platform, which uses artificial intelligence to design small‑molecule, peptide, and biologic therapies that cross the blood‑brain barrier and target secretory dysfunctions such as Alzheimer’s disease and type II diabetes. Early organoid studies demonstrate rapid reversal of Alzheimer’s pathology, highlighting a novel mechanism‑of‑action beyond symptomatic treatment.
Pulse Analysis
Proscia’s recent KLAS accolade underscores a maturing digital pathology market where laboratories prioritize integrated, high‑performing software. The 95.2 score reflects not only robust image analysis capabilities but also strong customer support, operational reliability, and perceived value—factors that drive procurement decisions in an industry facing mounting pressure to accelerate diagnostic turnaround. As hospitals and research institutions expand their virtual slide repositories, vendors that demonstrate consistent excellence across culture, loyalty, operations, product, relationship, and value are poised to capture a larger share of the multi‑billion‑dollar pathology spend.
Porosome Therapeutics is leveraging its Porosome.AI platform to address a long‑standing gap in drug development: delivering therapeutics that modulate intracellular secretion mechanisms while traversing the blood‑brain barrier. By combining AI‑guided molecule design with cryo‑EM validation, the company has generated three distinct modalities—small molecules, engineered peptides, and reconstituted biologics—each aimed at restoring porosome function in diseases marked by secretory failure. The rapid reduction of tau and phosphorylated‑tau in Alzheimer’s organoid models suggests a disease‑modifying potential that could shift the therapeutic landscape from symptomatic management to cellular repair.
Both stories illustrate a broader trend of artificial intelligence reshaping life‑science workflows. In pathology, AI enhances image interpretation, workflow efficiency, and data integration, fostering a more data‑driven diagnostic ecosystem. In drug discovery, AI accelerates target identification and candidate optimization, reducing time‑to‑clinic for high‑risk indications. Investors and industry leaders are watching these developments closely, as successful AI applications promise not only clinical breakthroughs but also scalable, cost‑effective solutions that could redefine value creation across biotech and med‑tech sectors.
Comments
Want to join the conversation?